Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG06466 in PTSD: fMRI and Sleep Effects
NCT04597450Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABX-1431 in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Lundbeck. Primary endpoints: Mean Blood Oxygen Level Dependent Percent Signal Change During Facial Affect Recognition Task at Day 15, Mean Blood Oxygen Level Dependent Percent Signal Change During Threat Processing Task at Day 15 and 8 more. Started Sep 2020; status: completed.
02
Drugs
ABX-1431
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04597450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597450.